September 16, 2026 7:30am EDT CLEVELAND, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a commercial-stage biopharmaceutical company developing genetic medicines for serious diseases with high unmet need, today…
September 16, 2026 7:30am EDT
CLEVELAND, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a commercial-stage biopharmaceutical company developing genetic medicines for serious diseases with high unmet need, today announced the activation of University of Florida Health (UF Health) in Gainesville, Florida, as the eighth Qualified Treatment Center (QTC) for the administration of ZEVASKYN (prademagene zamikeracel) gene-modified cellular sheets. ZEVASKYN is the first and only autologous gene-modified cellular sheets for the treatment of wounds in patients with recessive dystrophic epidermolysis bullosa (RDEB).
“Activation of UF Health as a QTC represents an important step in expanding access to ZEVASKYN for patients living with RDEB in Florida and the Southeastern United States,” said Dr. Madhav Vasanthavada, Chief Commercial Officer of Abeona. “UF Health is widely recognized for its leadership in dermatology and multidisciplinary patient care, and we are excited to partner with them to bring this innovative gene therapy to eligible children and adult patients in need.”
“The University of Florida Health is now the sole treatment center for ZEVASKYN across the Southeastern United States. This new gene therapy expands the treatment armamentarium for managing epidermolysis bullosa, with the goal of improving skin healing and patient quality of life,” said Michael Lavery, M.D., Clinical Assistant Professor in the Department of Dermatology at the University of Florida and Director of the University of Florida Epidermolysis Bullosa Multidisciplinary Clinic.
“ZEVASKYN brings together the expertise of our Pediatric Surgery and Burn teams and highlights the collaborative care model that defines UF Health. We are proud to partner with Abeona Therapeutics to expand access to specialized treatment for patients with epidermolysis bullosa,” said Dr. Shawn Larson, M.D., Professor and Chief of the Division of Pediatric Surgery at the University of Florida.
UF Health has already initiated patient identification and onboarding activities and is working with Abeona to support treatment access for eligible patients. For more information about receiving ZEVASKYN treatment at UF Health, contact the UF Health Epidermolysis Bullosa (EB) Clinic in Gainesville by calling (352) 594-1500, or by email at [email protected]
. For more information, visit: https://dermatology.med.ufl.edu/patient-care/epidermolysis-bullosa-ebclinic/
.
For more information on how to access ZEVASKYN and learn about patient support services offered through Abeona Assist™, Abeona's comprehensive patient support program, visit www.abeonaassist.com
, call 1-855-ABEONA-1 (1-855-223-6621) or email [email protected]
. Abeona Assist offers personalized support, including helping eligible patients understand their insurance benefits and financial assistance options, and providing travel and logistical assistance.
About recessive dystrophic epidermolysis bullosa
Recessive dystrophic epidermolysis bullosa (RDEB), a rare blistering disorder without a cure, is characterized by severe skin wounds that cause pain and can lead to systemic complications impacting the length and quality of life. People with RDEB have a defect in both copies of the COL7A1 gene, leaving them unable to produce functioning type VII collagen, which is necessary to anchor the dermal and epidermal layers of the skin.
About ZEVASKYN**®** (prademagene zamikeracel) gene-modified cellular sheets
ZEVASKYN is the first and only autologous cell sheet-based gene therapy for the treatment of wounds in adult and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). RDEB is a severe skin disease caused by a defect in both copies of the COL7A1 gene resulting in the inability to produce functional type VII collagen. Without functional type VII collagen and anchoring fibrils, the skin is fragile and blisters easily, leading to wounds that continually open and close, or fail to heal altogether. Patients often have large open wounds that can lead to serious life-threatening complications. ZEVASKYN incorporates the functional type VII collagen-producing COL7A1 gene into a patient's own skin cells, ex vivo, using a replication-incompetent retroviral vector to produce functional type VII collagen in treated wounds. ZEVASKYN has demonstrated clinically meaningful wound healing and pain reduction with a single surgical application. For more information, visit www.ZEVASKYN.com
.
Indication
ZEVASKYN® (prademagene zamikeracel) is an autologous cell sheet-based gene therapy indicated for the treatment of wounds in adult and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB).
Important Safety Information
Serious allergic reactions to ZEVASKYN can occur. Patients should get medical help right away if they experience symptoms like itching, swelling, hives, difficulty breathing, runny nose, watery eyes, or nausea. In rare cases, a severe reaction called anaphylaxis may happen. There is a potential risk that treatment with ZEVASKYN may contribute to the development of cancer because of how the therapy works. Patients should be monitored for the rest of their lives to check for any signs of cancer.
ZEVASKYN is made using human and animal materials. Although these materials are tested before use, the risk of passing on infections cannot be eliminated. The most common side effects are pain from the procedure and itching.
This is not a complete list of side effects. Patients should call their care team for medical advice about side effects. Side effects may be reported to Abeona at 1-844-888-2236 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. See full Prescribing Information.
About Abeona Therapeutics
Abeona Therapeutics Inc. is a commercial-stage biopharmaceutical company developing cell and gene therapies for serious diseases. Abeona’s ZEVASKYN® (prademagene zamikeracel) is the first and only autologous cell-based gene therapy for the treatment of wounds in adult and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). The Company’s fully integrated cell and gene therapy cGMP manufacturing facility in Cleveland, Ohio, serves as the manufacturing site for ZEVASKYN commercial production. The Company’s development portfolio features ABO-701 (PSMA-SIR-T™), a potentially first-in-class engineered T-cell therapy targeting PSMA, engineered to overcome the core failures of cell therapies in solid tumors. For more information, visit www.abeonatherapeutics.com
.